Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea (NCT02268474) | Clinical Trial Compass
CompletedNot Applicable
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
United States22 participantsStarted 2014-09
Plain-language summary
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.
Who can participate
Age range20 Years – 80 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Females or Males, 20 to 80 years of age (inclusive).
✓. Fitzpatrick Skin Type I - III.
✓. Clinical diagnosis of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
✓. Willing to refrain from using systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area.
✓. Must be able to read, understand and sign the Informed Consent Form.
✓. Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
✓. Wiling to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the face every day for the duration of the study, including the follow-up period.
✓. Willingness to have digital photographs taken of the face.
Exclusion criteria
✕. History of prior laser or light based procedures for the face within 6 months of study participation.
✕. Fitzpatrick Skin Type IV - VI.
✕. Pregnant and/or breastfeeding.
✕. Subject is less than 20 years of age or greater than 80 years of age.
✕. Having an infection, dermatitis or rash in the treatment area.
What they're measuring
1
Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea
✕. Suffering from significant concurrent illness, such as diabetes mellitus, cardiovascular disease, uncontrolled hypertension, or pertinent neurological disorders.
✕. History of keloid formation, hypertrophic scarring or of abnormal wound healing.
✕. History of immunosuppression/immune deficiency disorders such as psoriasis, eczema, vitiligo, or currently using immunosuppressive medications.